- Home
- AMPY vs PRLD Comparison
AMPY vs PRLD Comparison
Compare AMPY & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMPY | PRLD |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.9M | 207.5M |
| IPO Year | 2011 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AMPY | PRLD |
|---|---|---|
| Price | $6.02 | $3.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | ★ 1.3M | 197.9K |
| Earning Date | 05-11-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 232.26 | 23.21 |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $208,637,000.00 | $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | $14.60 | $100.00 |
| P/E Ratio | $6.06 | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $2.27 | $0.61 |
| 52 Week High | $6.79 | $4.19 |
Technical Indicators
Market Signals| Indicator | AMPY | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 48.72 | 62.88 |
| Support Level | $5.10 | $1.02 |
| Resistance Level | $6.67 | $4.10 |
| Average True Range (ATR) | 0.38 | 0.31 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 12.78 | 95.40 |
Price Performance
Historical ComparisonAbout AMPY Amplify Energy Corp.
Amplify Energy Corp is an independent oil and natural gas company engaged in the acquisition, development, exploitation, and production of oil and natural gas properties in the United States. The company's oil and natural gas properties are located in large, mature oil and natural gas reservoirs. The company assets consists of producing oil and natural gas properties located in Oklahoma, the Rockies, federal waters offshore Southern California, East Texas/North Louisiana and Eagle Ford.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.